Cargando…
Liraglutide attenuates hepatic iron levels and ferroptosis in db/db mice
Liver pathological changes are as high as 21%-78% in diabetic patients, and treatment options are lacking. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor that is widely used in the clinic and is approved to treat obesity and diabetes. However, the specific protection mechanism needs to be...
Autores principales: | Song, Ji-Xian, An, Ji-Ren, Chen, Qi, Yang, Xin-Yue, Jia, Cui-Ling, Xu, Shan, Zhao, Ya-shuo, Ji, En-Sheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161873/ https://www.ncbi.nlm.nih.gov/pubmed/35311455 http://dx.doi.org/10.1080/21655979.2022.2051858 |
Ejemplares similares
-
Effects of liraglutide on astrocyte polarization and neuroinflammation in db/db mice: focus on iron overload and oxidative stress
por: An, Ji-Ren, et al.
Publicado: (2023) -
Efficacy of Acetylshikonin in Preventing Obesity and Hepatic Steatosis in db/db Mice
por: Su, Mei-Ling, et al.
Publicado: (2016) -
Liraglutide reduces lipogenetic signals in visceral adipose of db/db mice with AMPK activation and Akt suppression
por: Shao, Yimin, et al.
Publicado: (2015) -
Berberine alleviates hyperglycemia by targeting hepatic glucokinase in diabetic db/db mice
por: Li, Meng, et al.
Publicado: (2019) -
Comparative Study of Liraglutide and Insulin Glargine on Glycemic Control and Pancreatic β-Cell Function in db/db Mice
por: Li, Yanli, et al.
Publicado: (2018)